Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Breakthrough: New Molecule Targets Liver Fat & Weight Loss

3 October 2026 · By · Wire by Fusion42

Published

3 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at hcplive.com →

◆ Verified

Fusion42 · 3 October 2026 · Fusion42 review

The SYNCHRONIZE-2 trial presented at EASD 2026 demonstrated that survodutide effectively reduces body weight in patients with obesity and type 2 diabetes. This advances new treatment options targeting liver fat and weight loss.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now explore a novel molecule that does more than weight loss by also targeting liver fat, opening new positioning and partnerships in diabetes care.

◆ Coverage

1 source · 3 Oct 2026

◆ Related on Wire

◆ Topics

Biotechweight-losstype-2-diabetesliver-fatclinical-trialsurvodutide